ArticleScience China. Life sciences2023

FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Guanglei Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.